Lu-Yao G, Nikita N, Keith SW, et al. - Via a population-based retrospective study, researchers evaluated the short-term outcomes of abiraterone acetate (AA) and enzalutamide (ENZ) in patients with pre-existing cardiovascular disease (CVD). At least one pre-existing CVD was seen in 67% of eligible participants (2,845 on AA and 1,031 on ENZ). Having one to two pre-existing CVDs was related to 16% higher 6-month mortality; the risk was higher among those having three or more CVDs vs those without pre-existing CVDs. Elderly prostate cancer individuals with pre-existing CVDs encountered greater short-term mortality than comparable individuals without CVDs, following treatment with AA or ENZ. Mortality correlated with CVDs was not impacted on whether they received AA vs ENZ.